Description
The standard antibiotic therapy of MRSA infections is parenterally administered vancomycin which is expensive, potentially toxic and requires monitoring of serum antibiotic concentrations.1 Teicoplanin, a parenteral glycopeptide with less nephrotoxicity, is an alternative agent although there is less published data on the efficacy of teicoplanin in the management of MRSA infections, and serum monitoring may still be required to ensure therapeutic levels in serious staphylococcal infections. Vancomycin (or teicoplanin) are sometimes combined with oral antibiotics (particularly rifampicin or fusidic acid) for the treatment of MRSA infections such as endocarditis, osteomyelitis, pneumonia or septicaemia. The
therapeutic advantage of such combinations has not been definitely established.
